Pietro Quaglino

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Martina Sanlorenzo, Igor Vujic, Adil Daud et al. · JAMA Dermatology · 2015 · 452 citations · Full text

Medicine, Oncology, Pharmacology +15

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Julia Scarisbrick, H. Miles Prince, Maarten H. Vermeer et al. · Journal of Clinical Oncology · 2015 · 421 citations · Full text

Medicine, Dermatology, Oncology +17

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Robert Knobler, Pia Moinzadeh, Nicolas Hunzelmann et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 261 citations · Full text

Medicine, Dermatology, Pathology +17